Prostate News and Research

RSS

China Sky One Medical passes the ICPBP examination for two of its new products

China Sky One Medical, Inc. ("China Sky One Medical" or "the Company"), a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company recently passed the Chinese National Institute for the Control of Pharmaceutical and Biological Products ("ICPBP") examination for two of its new products: its Diagnostic Kit for Human Prostate Specific Antigen (Colloidal Gold) and its Determination Kit for Luteinizing Hormone (Colloidal Gold).

26 Nov 2009

Aegis Breast 3.0 that offers powerful real-time 4D image processing to be launched

Sentinelle Medical Inc., a leading manufacturer of breast MRI coils and advanced visualization software launches a suite of new leading edge clinical applications on its Aegis(TM) medical imaging software platform at this year's Radiological Society of North America (RSNA) annual meeting in Chicago, Nov. 30 - Dec. 5, 2009 (Booth 5800, Hall A).

26 Nov 2009

Advanced radiation delivery techniques can reduce TomoTherapy treatment time

TomoTherapy Incorporated announced today that a research study published in the November 11, 2009 International Journal of Radiation Oncology * Biology * Physics -- commonly known as the Red Journal -- indicated that TomoTherapy(SM) treatment times could be reduced by up to 66 percent using advanced radiation delivery techniques.

25 Nov 2009

Emerging cancer vaccines: Forecasts, new developments and pipeline analysis

The H1N1 vaccine has spurred media interest in vaccines, as well as predictions of vaccines for a host of new diseases. According to Kalorama Information, certain cancers may be added to the list of diseases for which vaccinations will be employed.

25 Nov 2009

Initiation of Phase II clinical trial to evaluate the efficacy of BN83495 announced

Ipsen today announced the initiation of an international, multi-center, controlled, randomized Phase II clinical trial to evaluate the safety and efficacy of BN83495, its investigational first-in-class steroid sulfatase (STS) inhibitor, in advanced endometrial cancer.

25 Nov 2009

Seattle Genetics and Agensys expand ADC collaboration

Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Inc., an affiliate of Astellas, announced today an expansion of the companies’ antibody-drug conjugate (ADC) collaboration. Under the amended agreement, Agensys will pay a $12 million fee for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at the time of investigational new drug (IND) submission.

24 Nov 2009

ProUroCare Medical files 510(k) application for prostate mechanical imaging system

ProUroCare Medical Inc. (OTCBB: PUMD) (OTCBB: PUMDU) (OTCBB: PUMDW), a provider of proprietary medical imaging products, today announced that a 510(k) application for U.S. market clearance of a prostate mechanical imaging system has been filed with the Food & Drug Administration (FDA).

24 Nov 2009

LCA-NY issues 2009 Report Card on Lung Cancer

Today, Lung Cancer Alliance-New York (LCA-NY) issued its 1st Report Card on Lung Cancer. This Report is an assessment of progress being made against lung cancer in the state of New York. LCA-NY is a chapter of Lung Cancer Alliance (LCA), the only national organization dedicated exclusively to patient support and advocacy for people living with or at risk for lung cancer.

23 Nov 2009

Today's opinions and editorials

But when it comes to making medical care not only cheaper but also better, reducing hospital infections is among the easiest changes to make--something reform really should be able to do, even in this political universe of such limited possibility (Jonathan Cohn, 11/23).

23 Nov 2009

Winship-led team identifies a way to exploit cancer cells' taste for glucose

The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered.

23 Nov 2009

Cancer promoting gene identified

Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. Scientists hope the finding could lead to an effective therapy to target and inhibit the expression of this gene resulting in inhibition of cancer growth.

21 Nov 2009

Zoladex consumers entitled to treble damages, Court rules

The United States Court of Appeals for the First Circuit upheld an earlier District Court ruling yesterday, approving a settlement in the long-running Average Wholesale Price (AWP) pharmaceutical litigation against AstraZeneca Pharmaceuticals ( AZN).

21 Nov 2009

"Hotline" report on finasteride for prevention of prostate cancer

In response to a recent New York Times article that questions why currently available medications designed to treat and prevent some cancers are being ignored, ECRI Institute, an independent nonprofit organization, is offering a roadmap to the evidence on Finasteride for Prevention of Prostate Cancer for free download.

20 Nov 2009

FDA acknowledges Dendreon's amended BLA for PROVENGE as a complete response

Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).

20 Nov 2009

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis.

20 Nov 2009

2nd EMUC Meeting to discuss urological cancer

Experts agree that the urological cancer patient will benefit greatly if the delivered treatment is the result of a combined effort. Collaboration of experts from various fields is, therefore, necessary to take cancer-related research and medical practice to the next level.

20 Nov 2009

HHS Secretary commended for her statement on government medical panel

U.S. Health and Human Services Secretary Kathleen Sebelius is to be commended for publicly stating the government panel opposing mammograms is "an outside independent panel of doctors and scientists who ... do not set federal policy and ... don't determine what services are covered by the federal government."

20 Nov 2009

A selection of today's opinions and editorials

Everyone has been trying to come up with a good nickname for the 10 years we're concluding next month. Terror Era really sounds like too much of a downer. How about the Decade of Medical Backtracking? Somewhere between the reports that Pap smears and tests for prostate cancer aren't all they were cracked up to be and the news that a high fiber diet doesn't do anything to prevent cancer, the health establishment began looking decidedly nonomniscient. Then this week, a federal task force reported that most women don't need annual mammograms (Gail Collins, 11/18).

19 Nov 2009

EIN News launches "Mesothelioma News Today"

EIN News, an online leader in industry news monitoring and press syndication, has today added a new publication to its portfolio of health-related international news sites for industry professionals and analysts: Mesothelioma News Today (http://mesothelioma.einnews.com).

19 Nov 2009

Aperio Technologies receives U.S. patent for client/server image analysis

Aperio Technologies, Inc., (Aperio), a global leader in digital pathology for the healthcare and life sciences industry, announced today that the United States Patent and Trademark Office has issued the company patent No. 7,602,524 entitled "Image Processing and Analysis Framework."

19 Nov 2009